Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank33
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Percentile
P33
Within normal range
vs 2Y Ago
-11.6x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
2025$-123.48M+26.4%
2024$-167.80M-1671.5%
2023$10.68M+105.9%
2022$-182.40M-142.7%
2021$-75.15M-104.0%
2020$-36.85M-244.8%
2019$-10.69M-